Annexin Pharmaceuticals AB (publ) (STO:ANNX)

Market Cap	91.77M -54.9%
Revenue (ttm)	n/a
Net Income	-39.44M
EPS	-5.60
Shares Out	7.06M
PE Ratio	n/a
Forward PE	4.68
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,991
Open	12.50
Previous Close	12.50
Day's Range	11.95 - 13.10
52-Week Range	11.05 - 35.80
Beta	0.29
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 17, 2026

About STO:ANNX

Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions that is in phase 2 clinical phase for the treatment of ophthalmology, oncology, sickle cell disease, and cardiovascular disease. Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and is based in Stockholm, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 4
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ANNX

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 3, 2026

Data Sources Report a data error